Cargando…

High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity Is Improved by Treatment With Antiretroviral Therapy in Acute Human Immunodeficiency Virus Infection

BACKGROUND: Individuals infected with human immunodeficiency virus (HIV) have decreased high-density lipoprotein (HDL)-cholesterol and increased cardiovascular disease (CVD). Reverse cholesterol transport from macrophages may be inhibited by HIV and contribute to increased CVD. Human studies have n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lo, Janet, Rosenberg, Eric S., Fitzgerald, Michael L., Bazner, Suzane B., Ihenachor, Ezinne J., Hawxhurst, Victoria, Borkowska, Alison H., Wei, Jeffrey, Zimmerman, Chloe O., Burdo, Tricia H., Williams, Kenneth C., Freeman, Mason W., Grinspoon, Steven K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324225/ https://www.ncbi.nlm.nih.gov/pubmed/25734176 http://dx.doi.org/10.1093/ofid/ofu108

Ejemplares similares

Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV
por: Zanni, Markella V, et al.
Publicado: (2017)

Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States
por: Zanni, Markella V, et al.
Publicado: (2022)

Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Antiretroviral Refill Histories as a Predictor of Future Human Immunodeficiency Virus Viremia
por: Sokpa, Darryl, et al.
Publicado: (2022)

Aspirin Use for Primary and Secondary Prevention in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Patients
por: Suchindran, Sujit, et al.
Publicado: (2014)

Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals
por: Mosepele, Mosepele, et al.
Publicado: (2018)

Myocardial Fibrosis Among Antiretroviral Therapy-Treated Persons With Human Immunodeficiency Virus in South Africa
por: Shuldiner, Scott R, et al.
Publicado: (2020)

Visceral Adiposity Index as a Measure of Cardiovascular Disease in Persons With Human Immunodeficiency Virus
por: Thomas, Teressa S, et al.
Publicado: (2023)

Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus
por: Vernon, Frances, et al.
Publicado: (2020)

Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy
por: Riebensahm, Carlotta, et al.
Publicado: (2022)

Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
por: De Castro, Nathalie, et al.
Publicado: (2022)

Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis
por: Kay, Alexander, et al.
Publicado: (2022)

Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers
por: Chen, Wanyi, et al.
Publicado: (2023)

Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence
por: Oladele, Rita O., et al.
Publicado: (2016)

Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus
por: Desmonde, Sophie, et al.
Publicado: (2019)

Impact of Pharmacist-Driven Antiretroviral Stewardship and Transitions of Care Interventions on Persons With Human Immunodeficiency Virus
por: Brizzi, Marisa B, et al.
Publicado: (2020)

Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency Virus
por: Hall, Leangelo N., et al.
Publicado: (2017)

Dietary Patterns and Physical Activity Correlate With Total Cholesterol Independently of Lipid-Lowering Drugs and Antiretroviral Therapy in Aging People Living With Human Immunodeficiency Virus
por: Marzel, Alex, et al.
Publicado: (2018)

Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
por: Surial, Bernard, et al.
Publicado: (2023)

Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics
por: Li, Jonathan Z., et al.
Publicado: (2014)

Impact of an Antiretroviral Stewardship Team on the Care of Patients With Human Immunodeficiency Virus Infection Admitted to an Academic Medical Center
por: DePuy, Ashley M, et al.
Publicado: (2019)

The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment
por: Kamal, Susan, et al.
Publicado: (2017)

Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
por: Busca, C, et al.
Publicado: (2022)

Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2023)

Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy
por: Bernal, Silvia, et al.
Publicado: (2023)

Defective Monocyte Enzymatic Function and an Inhibitory Immune Phenotype in Human Immunodeficiency Virus-Exposed Uninfected African Infants in the Era of Antiretroviral Therapy( )
por: Afran, Louise, et al.
Publicado: (2022)

Physician Decisions to Defer Antiretroviral Therapy in Key Populations: Implications for Reducing Human Immunodeficiency Virus Incidence and Mortality in Malaysia
por: Ferro, Enrico G., et al.
Publicado: (2017)

Plasma Profiles of Inflammatory Markers Associated With Active Tuberculosis in Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Positive Individuals
por: Olsson, Oskar, et al.
Publicado: (2019)

A Qualitative Study of the Experience of Immediate Antiretroviral Therapy Among Urban Persons With Newly Diagnosed Human Immunodeficiency Virus
por: Christopoulos, Katerina A, et al.
Publicado: (2021)

Antiretroviral Initiation at ≥800 CD4+ Cells/mm(3) Associated With Lower Human Immunodeficiency Virus Reservoir Size
por: Rasmussen, Thomas A, et al.
Publicado: (2022)

Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy
por: Weiss, Julian J, et al.
Publicado: (2021)

Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
por: Lo Re, Vincent, et al.
Publicado: (2015)

Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes
por: Huang, Austin, et al.
Publicado: (2015)

Circulating β-d-Glucan as a Marker of Subclinical Coronary Plaque in Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus
por: Isnard, Stéphane, et al.
Publicado: (2021)

A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy
por: O’Brien, Meagan P., et al.
Publicado: (2017)

The Effect of Switching to Second-Line Antiretroviral Therapy on the Risk of Opportunistic Infections Among Patients Infected With Human Immunodeficiency Virus in Northern Tanzania
por: Ramadhani, Habib O., et al.
Publicado: (2016)

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
por: Ostrowski, Mario, et al.
Publicado: (2015)

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Martinello, Marianne, et al.
Publicado: (2016)

Am I Positive? Improving Human Immunodeficiency Virus Testing in the Era of Preexposure Prophylaxis and Immediate Antiretroviral Therapy Using Machine Learning
por: Zucker, Jason, et al.
Publicado: (2022)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8k06k5o3ai79oapdgjm6o6qlvt